6505--Buprenorphine Pre-solicitation notice
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA) National Acquisition Center has issued a solicitation for an uninterrupted supply of Buprenorphine HCL/Naloxone HCL Tablets. This procurement aims to establish national contract prices for distribution through the VA and Department of Defense (DOD) Pharmaceutical Prime Vendor Programs, also serving the Bureau of Prisons (BOP) and Indian Health Service (IHS). Proposals are due by February 3, 2026.
Scope of Work
The contractor will provide sublingual tablets in two strengths:
- Buprenorphine HCL 2mg/Naloxone HCL 0.5mg (Estimated 171,239 bottles of 30 count annually)
- Buprenorphine HCL 8mg/Naloxone HCL 2mg (Estimated 251,144 bottles of 30 count annually)
Key technical requirements include:
- Packaging: 30-count unit-of-use bottles (glass is not acceptable) with safety caps and specific dimensions.
- Compliance: Products must meet FDA cGMP standards and Drug Supply Chain Security Act (DSCSA) serialization requirements.
- Registration: Offerors must have a unique NDC and register product info with FDA and major drug databases within 5 days of award.
- Supply Chain: Non-manufacturers must provide a Letter of Commitment from the manufacturer.
Contract & Timeline
- Type: Firm Fixed-Price, Indefinite-Delivery Requirements contract.
- Duration: One-year base period plus four one-year option periods.
- Set-Aside: Unrestricted.
- Response Due: February 3, 2026, at 2:30 PM CST (per Amendment 0002).
- Implementation: Maximum 60-day period from award.
Evaluation
Award will be made to the responsible offeror providing the Lowest Price Technically Acceptable (LPTA) proposal. Technical factors include product description compliance, NDC uniqueness, FDA approval, and manufacturing facility clearance.
Additional Notes
Offerors must have an executed Master Agreement and Pharmaceutical Pricing Agreement with VA FSS. Non-small businesses must submit a subcontracting plan for contracts exceeding $750,000. All prices must include a 0.5% Cost Recovery Fee.